Apimeds Pharmaceuticals US, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Apimeds Pharmaceuticals US, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 95% of its market value (net debt). Lower than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-1.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 66% of Healthcare companies in United States.
Cash Cushion Ratio
−95%Debt, after subtracting cash, equals 95% of its market value (net debt).
Lower than 94% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Apimeds Pharmaceuticals US, Inc. made a loss over the last year. Apimeds Pharmaceuticals US, Inc. owes $0.17 for every $1 it owns. Apimeds Pharmaceuticals US, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossApimeds Pharmaceuticals US, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.04The share price is 0.04 times Apimeds Pharmaceuticals US, Inc.'s book value per share, lower than almost all Healthcare companies in United States.
Market cap
$4 MThe total market value of all of Apimeds Pharmaceuticals US, Inc.'s shares at today's price (share price × number of shares), smaller than 94% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$106 MWhat Apimeds Pharmaceuticals US, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$70.54Net worth divided by the number of shares. The share price of $2.89 is 0.0 times this, which is the P/B above.
Owes vs Owns
0.17×Apimeds Pharmaceuticals US, Inc. owes $0.17 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Dividend yield
NoneApimeds Pharmaceuticals US, Inc. does not currently pay a dividend.
Profit growth
LossApimeds Pharmaceuticals US, Inc. made a loss in each of the last two years.
Interest cover
Not coveredApimeds Pharmaceuticals US, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtApimeds Pharmaceuticals US, Inc. had $4 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Apimeds Pharmaceuticals US, Inc.: $4 M ÷ $106 M (30 Jun 2026) = 0.0.
How much does Apimeds Pharmaceuticals US, Inc. owe compared with what it owns?
Apimeds Pharmaceuticals US, Inc. owes $0.17 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Does Apimeds Pharmaceuticals US, Inc. pay a dividend?
No. Apimeds Pharmaceuticals US, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.